Format

Send to

Choose Destination
Bioorg Med Chem Lett. 2006 Jul 15;16(14):3789-92. Epub 2006 May 5.

3-Benzimidazol-2-yl-1H-indazoles as potent c-ABL inhibitors.

Author information

1
Small Molecule Drug Discovery, Medicinal Chemistry Department, Chiron Corporation, 4560 Horton Street, Emeryville, CA 94608, USA.

Abstract

The 3-benzimidazol-2-yl-1H-indazole scaffold was developed as an alternate scaffold for our receptor tyrosine kinase (RTK) inhibitor program. In exploring the SAR of this series, it was discovered that a subset of these compounds potently inhibit the enzyme c-ABL. The SAR of these compounds is described.

PMID:
16678414
DOI:
10.1016/j.bmcl.2006.04.043
[Indexed for MEDLINE]

Supplemental Content

Full text links

Icon for Elsevier Science
Loading ...
Support Center